Pitt Scientists Uncover 2-Gene Melanoma Mechanism That Lengthens Telomeres
Updated
Updated · SciTechDaily · May 16
Pitt Scientists Uncover 2-Gene Melanoma Mechanism That Lengthens Telomeres
1 articles · Updated · SciTechDaily · May 16
University of Pittsburgh researchers found melanoma cells become effectively immortal by pairing TERT promoter mutations with ACD/TPP1 promoter mutations, a combination that dramatically lengthens telomeres.
About 75% of melanoma tumors carry TERT mutations, but those alone could not explain the unusually long telomeres seen in patients; the newly identified TPP1 changes help recruit telomerase directly to chromosome ends.
Roughly 5% of cutaneous melanoma cases show the TPP1 promoter mutations, and they often appear alongside—not instead of—TERT mutations, supporting a cooperative two-part mechanism.
Cells engineered with both mutated genes produced telomere lengths that closely matched melanoma tumors, giving researchers a clinical explanation for a long-standing puzzle.
The Science study points to TPP1 as a potential therapeutic target in melanoma, where telomere maintenance appears especially critical for cells to bypass normal aging limits.
Why did sun-exposed skin cells evolve a unique two-gene 'immortality' hack, and what does this reveal about cancer's evolution?
Can advanced gene sequencing now predict a tumor's aggression by spotting the specific genetic tricks that make melanoma immortal?
As melanoma uses multiple tricks to survive, which is a better drug target: its genetic 'immortality switch' or its metabolic vulnerabilities?
Cracking Melanoma’s Code: The Synergistic Role of TERT and TPP1/ACD in Cancer Immortality and Therapy
Overview
In late 2025, University of Pittsburgh scientists made a major breakthrough by discovering that aggressive melanoma cells achieve cellular immortality through the combined action of two genes: TERT and TPP1/ACD. Normally, telomeres—protective caps on chromosomes—shorten with each cell division, eventually signaling cells to stop dividing and die, which prevents uncontrolled growth. However, melanoma cells bypass this limit because TERT produces telomerase to rebuild telomeres, while TPP1/ACD helps protect and regulate them. This synergy allows melanoma cells to keep dividing indefinitely, revealing a new target for more effective cancer treatments.